Today, pharmaceutical stocks hit the daily limit! It just fell below 3,000 points two days ago, and in a blink of an eye, it was about to recover 3,100 points! The big counterattack is really exciting!
Open the market software, what a guy, the pharmaceutical stocks are soaring, and ETFs are hitting the daily limit!
When the new energy analysts were still mocking the pharmaceutical sector for not having any capital inflows, on the 14th, all the water rushed to the pharmaceutical sector!
Next, let’s analyze the reasons for today’s big rise.
First, the global market counterattack, A shares confidence repair
Second, there is good news in the pharmaceutical sector.
Dongwu Securities analysis has four factors: a large counterattack is expected in the fourth quarter! Four factors lead to the exhaustion of the short-selling in the pharmaceutical sector. The four factors lead to the exhaustion of the short-selling
, and a large counterattack is expected in the fourth quarter.
One of them recovered after the epidemic and medical insurance expenditures grew steadily. The changes in precise and scientific prevention and control of the epidemic are conducive to the increase in prescription drugs and the recovery of consumer medical care; annual medical insurance fund expenditure increases by more than 12%, and the pharmaceutical industry is still continuing to grow.
The second is the innovative drug policy to recover. A series of policies such as simple renewal of innovative drugs, innovative drugs encourage some single-arm clinical trials, and DRG exemptions for innovative drugs will help the healthy development of domestic innovative drugs.
The third pharmaceutical sector has a low valuation and is at a low level in the past decade.
Fourth, from the fund allocation ratio, the standard configuration of pharmaceuticals is about 7.5%, and the full-based allocation ratio is about 6.4%, indicating that the pharmaceutical sector is low-profile by public fund , the short-selling pharmaceutical sector is exhausted, and the low-level pharmaceutical sector is inherently driven by valuation repair. In short, the resonance between the third quarter report and the valuation switching will be the main stock selection direction in October.
Debang Pharmaceutical analyst said that the Jiangxi Biochemical Cyberspace Administration was issued last night. The procurement policy was relatively mild and better than expected, leading to the chance of reversing the dilemma of IVD (refer to orthopedics)! In addition, the policy of simple renewal of medical insurance is clear and predictable, and the innovative medical devices in are not centralized for procurement, and the centralized procurement of dental implants and and orthopedics are better than expected. Pharmaceutical rose 5% today; the leading WuXi AppTec , Hengrui Medicine , Mindray Medical , etc. rose 8%! ! We think this is just the starting point of the pharmaceutical market! ! It is strongly recommended to boldly increase your investment in medicine! !
Debang Pharmaceutical said that the policy bottom, valuation bottom and configuration bottom are currently the starting point of the pharmaceutical bull market! ! Manufacturing, consumption and technology may rise in turn! It is strongly recommended to boldly increase your investment in medicine!
West China Medicine analyzed that: holdings bottom, holdings full-based holdings should have hit a new low in the past 10 years. Everyone has very few bargaining chips for medicine.
valuation bottom, the valuation level of the pharmaceutical sector next year, and from the perspective of PEG, should also be the lowest in the past 10 years. The overall valuation level is similar to the end of 2018, but the valuation of many stocks has hit new lows.
policy expectation bottom, is the easiest thing to be ignored by non-pharmaceutical industry investors, or even the partners of the pharmaceutical industry themselves are ignored or confused. It is that since the 4+7 centralized procurement in 2018, the centralized procurement has been implemented for almost 4 years. The impact of centralized procurement on the pharmaceutical sector has spread and penetrated into every category, such as Lepu Medical , Hengrui Medicine, etc. The existing revenue and profit part has fully reflected the impact of centralized procurement. It will start to be lightly installed later. Some companies have not yet performed centralized procurement for some categories, but as long as there is a greater possibility, the market expectation has long been priced into the stock price trend. Therefore, we believe that centralized procurement is no longer a new thing for the pharmaceutical industry, and its impact has even been reflected almost. In the future, it is expected to be lightweight and grow by relying on incremental varieties. Even the industry has shown positive trends at the policy level, such as the market expects the price increase of domestic stents, such as the national dental implant procurement policy far better than expected and the previous Ningbo dental implant policy.
Third, the photovoltaic sector also ushered in good news.On the news front, the United States suspended the imposition of anti-dumping and anti-subsidy tariffs on imported solar cells and components. The anti-subsidy tariff process for these imported batteries and components has been implemented for two years.
According to the announcement, the Biden administration temporarily exempts all anti-dumping or anti-subsidy duties imposed on solar cells and components assembled in Cambodia , Malaysia , Thailand or Vietnam using parts made in Cambodia , Malaysia , Thailand or Vietnam.
[Guojin Electric New] Photovoltaics: Southeast Asia's duty-free order has been confirmed and implemented. The trend of shipments to the United States and the US policy trend have improved marginally. The high demand has increased and the certainty has increased. We will continue to recommend it!
On October 14, the U.S. government announced the "final provisions" to implement the presidential announcement, temporarily exempting all anti-dumping or anti-subsidy duties imposed on solar cells and components assembled in Cambodia, Malaysia, Thailand or Vietnam using parts made in China. At the same time, the US Department of Commerce pointed out that all goods that benefit from this rule must be used in the United States within 180 days after the use deadline to solve the stockpiling problem.
has the following impact on the industry:
"final regulations" clearly suspend the imposition of "double anti-double" tariffs on import components in Southeast Asia, and marginal marginal shipments to the United States are improved. As the regional market with the highest cost tolerance, the United States will further drive the industry prosperity in Q4 and 2023, boosting market confidence in demand growth.
The United States centralized power station and bundled energy storage projects resume construction, and relevant centralized inverter, energy storage, and tracking bracket suppliers benefit marginally ( Sungrow Power Supply , Yihua Co., Ltd., etc.).
Southeast Asian battery/module production capacity can recover the ability to obtain excess profits ( Longi , Tianhe , Jingao, Jingke and other component leaders).
industry demand continues to be strong: the quotation of battery cells before the holiday has been raised for the second time in the month, reflecting that the demand end bearability has exceeded expectations again. In October, silicon material supply and component production continued to increase by about 10%, and the situation of strong supply and demand is clear. In the following Q4 of the industry enters the peak demand season, coupled with the accelerated release of silicon material production at the supply side, the industry's Q4 is likely to show a high prosperity state of "a mild decline in silicon material/component prices and continuous increase in volume." Looking ahead, as the release of silicon material supply drives the decline in component prices, the demand for medium- and short-term centralized ground power plants in major markets such as China, the United States and Europe is extremely elastic. We believe that the actual demand (the output scale of the module end) in 2023 is highly likely to exceed the current market consensus expectations of around 400GW and reach the range of 450-500GW. The strong performance of industrial chain prices in the process of continued increase in Q4 silicon material supply will be an important catalyst to increase the market's expectations for next year's demand prosperity!
stocks showed a general upward trend, with nearly 4,500 stocks in the two markets turning red, with a turnover of 861.7 billion yuan today. As of the close of the market, the Shanghai Composite Index rose 1.84%, the Shenzhen Component Index rose 2.81%, and the ChiNext Index rose 3.55%.
A total of 4,512 stocks rose in the two markets, 109 stocks hit the daily limit, 367 stocks fell, and northbound funds net bought nearly 7.5 billion yuan.
Forgot 15 years after stocks were recovered 10,000 yuan after stocks were recovered 10,000 yuan
Recently, in Taizhou, Zhejiang, according to Taizhou Traffic Radio, a villager, Master Chen, forgot that the stocks he bought for 10,000 yuan 15 years ago was found by the bank staff, and it turned out to be worth 500,000 yuan. Bank staff said that when they checked the account information, they found that his account information was very old and that the investment made a large proportion of profits. Therefore, they inferred that Master Chen should have forgotten this account. Master Chen said that he didn't expect that he would suddenly have so much money.
OK, that’s it today. I wish you all a happy weekend!
This article is from China Fund News
